Amyris, Inc.

AMRSQ

US03236M2008

Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâs sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.

Sector

Specialty Chemicals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AMYRIS, INC.	-40.00%	558K
ECOLAB INC.	+9.99%	62.67B
SIKA AG	-6.50%	45.97B
GIVAUDAN SA	+13.40%	39.51B
FUJIFILM HOLDINGS CORPORATION	+17.90%	26.04B
EMS-CHEMIE HOLDING AG	+1.03%	17.71B
CELANESE CORPORATION	-0.59%	17.25B
SYMRISE AG	+5.78%	15.44B
POSCO FUTURE M CO., LTD.	-29.39%	14.54B
ALBEMARLE CORPORATION	-22.38%	13.14B

Other Specialty Chemicals

Market Closed - OTC Markets Other stock markets 03:40:48 2024-04-19 pm EDT			5-day change	1st Jan Change
0.0015 ^USD	0.00%		-70.00%	-40.00%

Mar. 13	North American Morning Briefing : Stock Futures -2-	DJ
Jan. 22	Third Amended Joint Reorganization Plan Filed by Amyris, Inc.	CI

North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Third Amended Joint Reorganization Plan Filed by Amyris, Inc.	Jan. 22	CI
Notice for Auction Cancellation Filed by Amyris, Inc.	Jan. 16	CI
Foris Ventures Provides Information to the Shareholders	Jan. 05	CI
Advance Auto Parts Names Elizabeth Dreyer as Chief Accounting Officer	Jan. 05	MT
First Motion for Exclusivity Period Extension Approved For Amyris, Inc.	Jan. 04	CI
Amyris, Inc., Amyris Clean Beauty, Inc., and Aprinnova, LLC Enter into Amendment to That Certain Senior Secured Super Priority Debtor in Possession Loan Agreement	Jan. 04	CI
Motion for Asset Sale Approved for Amyris, Inc.	Jan. 03	CI
Dr. Reddy's Laboratories Acquires MenoLabs Business	Jan. 03	MT
Mounting Geopolitical Tensions Weigh Down Indian Equities on Wednesday	Jan. 03	MT
Dr. Reddy's Acquires Women's Health and Diery Supplements Brand MenoLabs	Jan. 03	MT
Amyris, Inc. cancelled the transaction announced on December 29, 2022	Dec. 28	CI
Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024	Dec. 27	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Bidding Procedure Approved for Amyris, Inc.	Dec. 19	CI
Motion for Asset Sale Filed by Amyris, Inc.	Dec. 14	CI
Notice of Selection of Successful Bidder by Amyris, Inc.	Dec. 13	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 11	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 11	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 11	CI
First Motion for Exclusivity Period Extension Filed by Amyris, Inc.	Dec. 06	CI
Second Amended Reorganization Plan Filed by Amyris, Inc.	Dec. 05	CI
THG buys skincare brand Biossance for USD20 million	Dec. 05	AN

Amyris, Inc.

Equities

AMRSQ

US03236M2008

Specialty Chemicals

Latest news about Amyris, Inc.

Chart Amyris, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Specialty Chemicals